Compare Abeona Therapeutics Inc (ABEO) vs AMC ENTERTAINMENT HOLDINGS, INC. (AMC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs AMC ENTERTAINMENT HOLDINGS, INC. — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while AMC ENTERTAINMENT HOLDINGS, INC. trades at $1.95 (market cap $1.54B). The key difference: AMC ENTERTAINMENT HOLDINGS, INC. is far larger — about 4.1× Abeona Therapeutics Inc's market cap, and AMC ENTERTAINMENT HOLDINGS, INC. pays a 0.11% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | AMC | |
|---|---|---|
Market Cap | $373.32M | $1.54B |
Sector | Health | Media |
52-Week High | $7.23 | $3.54 |
52-Week Low | $4.17 | $0.95 |
Enterprise Value | $228.22M | $9.13B |
Dividend Yield | — | 0.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
AMC trades at $1.72, down 8.99% in the last session amid dilution concerns from recent equity offerings. The stock shows bearish technical signals with negative cash flows and a net loss of $632.4M in 2025. Recent news highlights summer box office strength but ongoing investor worries about share dilution and profitability. The company's debt remains high at $4.01B, though revenue reached $4.85B in 2025.
Outlook remains challenged by persistent losses and high leverage, though diversification into live events offers growth potential. Key risks include dilution from equity sales and weak cash generation. Analyst consensus is mixed with a $1.85 price target, suggesting limited upside from current levels amid fundamental headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About AMC ENTERTAINMENT HOLDINGS, INC.
AMC Entertainment Holdings, Inc. operates as a holding company. The Company, through its subsidiaries, provides theatrical exhibition, movie screening, food distribution, online ticket booking, and other related services. AMC Entertainment offers movie theaters worldwide.
Read more on AMC →
